Synthesis, characterization, conformational analysis of a cyclic conjugated octreotate peptide and biological evaluation of 99mTc-HYNIC-His 3-Octreotate as novel tracer for the imaging of somatostatin receptor-positive tumors

Amino Acids

Volumn 44, Issue 3, 2013, Pages 933-946

  Behera, Ashok ^a   Banerjee, Indranil ^a   De, Kakali ^a   Munda, Rudra Narayan ^a   Chattopadhayay, Sankha ^b   Samanta, Amalesh ^c   Sarkar, Bharat ^d   Ganguly, Santanu ^d   Misra, Mridula ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^b Regional Centre   (India)

^c JADAVPUR UNIVERSITY   (India)

^d Regional Radiation Medicine Centre Thakurpukur Cancer Research Centre   (India)

Author keywords

Binding affinity; C6 glioma cell; Internalization study; Solid phase peptide synthesis; SSTR

Indexed keywords

SOMATOSTATIN RECEPTOR; TECHNETIUM HYDRAZINONICOTINIC ACID HISTONE H3 OCTREOTATE PEPTIDE TC 99M; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA SHEET; CARBON NUCLEAR MAGNETIC RESONANCE; CIRCULAR DICHROISM; CONTROLLED STUDY; CORRELATIONAL SPECTROSCOPY; DIAGNOSTIC IMAGING; DOSE TIME EFFECT RELATION; DRUG CONFORMATION; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG PURIFICATION; DRUG PURITY; DRUG RECEPTOR BINDING; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TUMOR LEVEL; DRUG UPTAKE; GLIOMA; HETERONUCLEAR MULTIPLE BOND CORRELATION; HETERONUCLEAR SINGLE QUANTUM COHERENCE; IC 50; IN VITRO STUDY; INFRARED SPECTROSCOPY; INTERNALIZATION; ISOTOPE LABELING; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN SECONDARY STRUCTURE; PROTON NUCLEAR MAGNETIC RESONANCE; QUALITY CONTROL; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SOLID PHASE SYNTHESIS; TUMOR DIAGNOSIS;

ANIMALS; CELL LINE, TUMOR; HUMANS; MALE; MOLECULAR IMAGING; NEOPLASMS; ORGANOTECHNETIUM COMPOUNDS; PEPTIDES, CYCLIC; RADIOPHARMACEUTICALS; RATS; RATS, INBRED LEW; RATS, SPRAGUE-DAWLEY; RECEPTORS, SOMATOSTATIN; SOLID-PHASE SYNTHESIS TECHNIQUES; TISSUE DISTRIBUTION;

RATTUS;

EID: 84876213133     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-012-1423-7     Document Type: Article

References (35)

1. Abrams MJ, Juweid M, Tenkate CI, Schwartz DA, Hauser MM, Gaul FE, Fuccello AJ, Rubin RH, Strauss HW, Fischman AJ (1990) Technetium-99m-human polyclonal igG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med 31(12):2022-2028
2. 1-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors-synthesis, radiolabeling and invitro validation. Life Sci 49(22):1583-1591
3. Bangard M, Behe M, Guhlke S, Otte R, Bender H, Maecke HR, Biersack HJ (2000) Detection of somatostatin receptor-positive tumours using the new Tc-99m-tricine-HYNIC-D-Phe(1)-Tyr(3)-octreotide: first results in patients and comparison with In-111-DTPA-D-Phe(1)-octreotide. Eur J Nucl Med 27(6):628-637
4. Barbieri F, Pattarozzi A, Gatti M, Porcile C, Bajetto A, Ferrari A, Culler MD, Florio T (2008) Somatostatin receptors 1, 2, and 5 cooperate in the somatostatin inhibition of C6 glioma cell proliferation in vitro via a phosphotyrosine phosphatase-eta-dependent inhibition of extracellularly regulated kinase 1/2. Endocrinology 149(9):4736-4746
5. 3 octreotide: a somatostatin receptor positive tumour imaging agent. J Radioanal Nucl Chem 290(1):123-129
6. Berges JA, Fisher AE, Harrison PJ (1993) A comparison of Lowry, Bradford and Smith protein assays using different protein standards and protein isolated from the marine diatom Thalassiosira pseudonana. Mar Biol 115(2):187-193
7. Breeman WAP, de Jong M, Kwekkeboom DJ, Valkema R, Bakker WH, Kooij PPM, Visser TJ, Krenning EP (2001) Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 28(9):1421-1429
8. De Jong M, Breeman WAP, Bakker WH, Kooij PPM, Bernard BF, Hofland LJ, Visser TJ, Srinivasan A, Schmidt MA, Erion JL, Bugaj JE, Macke HR, Krenning EP (1998) Comparison of In-111-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res 58(3):437-441
9. 111In- octreotide. J Nucl Med 41(6):1114-1119
10. Fischman AJ, Babich JW, Strauss HW (1993) A ticket to ride: peptide radiopharmaceuticals. J Nucl Med 34(12):2253-2263
11. Gabriel M, Decristoforo C, Maina T, Nock B, von Guggenberg E, Cordopatis P, Moncayo R (2004) 99mTc-N4-[Tyr3]Octreotate Versus 99mTc-EDDA/HYNIC-[Tyr3] Octreotide: an intrapatient comparison of two novel Technetium-99m labeled tracers for somatostatin receptor scintigraphy. Cancer Biother Radiopharm 19(1):73-79. doi: 10.1089/108497804773391702
12. Gandomkar M, Najafi R, Shafiei M, Mazidi M, Ebrahimi SES (2007) Preclinical evaluation of Tc-99m/EDDA/tricine/HYNIC0, 1-Nal(3), Thr(8)-octreotide as a new analogue in the detection of somatostatin-receptor- positive tumors. Nucl Med Biol 34(6):651-657. doi: 10.1016/j.nucmedbio.2007.06. 006
13. Gardiner J, Langenegger D, Hoyer D, Beck AK, Mathad RI, Seebach D (2008) The enantiomer of octreotate binds to all five somatostatin receptors with almost equal micromolar affinity - a comparison with SANDOSTATIN. Chem Biodivers 5(7):1213-1224. doi: 10.1002/cbdv.200890110
14. Grace CRR, Erchegyi J, Samant M, Cescato R, Piccand V, Riek R, Reubi JC, Rivier JE (2008) Ring size in octreotide amide modulates differently agonist versus antagonist binding affinity and selectivity. J Med Chem 51(9):2676-2681. doi: 10.1021/jm701445q
15. Kelly SM, Price NC (2000) The use of circular dichroism in the investigation of protein structure and function. Curr Protein Pept Sci 1(4):349-384. doi: 10.2174/1389203003381315
16. Koenig JA, Kaur R, Edwardson JM, Humphrey PPA (1996) Somatostatin receptors in Neuro2A neuroblastoma cells: pharmacological characterisation and internalisation of I-125-BIM-23027, a somatostatin analogue. Br J Pharmacol 118:P26
17. Koenig JA, Edwardson JM, Humphrey PPA (1997) Somatostatin receptors in Neuro2A neuroblastoma cells: operational characteristics. Br J Pharmacol 120(1):45-51
18. Krenning EP, Bakker WH, Kooij PPM, Breeman WAP, Oei HY, Dejong M, Reubi JC, Visser TJ, Bruns C, Kwekkeboom DJ, Reijs AEM, Vanhagen PM, Koper JW, Lamberts SWJ (1992) Somatostatin receptor scintigraphy with Indium-111-DTPA-D- Phe-1-octreotide in man: metabolism, dosimetry and comparison with Iodine-123-Tyr-3-octreotide. J Nucl Med 33(5):652-658
19. Lee TW, Chang SR, Chen ST, Tsai ZT (1998) Convenient solid-phase synthesis of tyr(3)-octreotide. Appl Radiat Isot 49(12):1581-1586. doi: 10.1016/s0969-8043(98)00003-7
20. Lewis JS, Lewis MR, Srinivasan A, Schmidt MA, Wang J, Anderson CJ (1999) Comparison of four Cu-64-labeled somatostatin analogues in vitro and in a tumor-bearing rat model: evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy. J Med Chem 42(8):1341-1347. doi: 10.1021/jm980602h
21. Liu S, Edwards DS (1999) Tc-99m-labeled small peptides as diagnostic radiopharmaceuticals. Chem Rev 99(9):2235-2268. doi: 10.1021/cr980436l
22. Liu S, Edwards DS, Barrett JA (1997) Tc-99m labeling of highly potent small peptides. Bioconjug Chem 8(5):621-636. doi: 10.1021/bc970058b
23. Maina T, Nock B, Nikolopoulou A, Sotiriou P, Loudos G, Maintas D, Cordopatis P, Chiotellis E (2002) Tc-99m demotate, a new Tc-99m-based Tyr(3) octreotate analogue for the detection of somatostatin receptor-positive tumours: synthesis and preclinical results. Eur J Nucl Med Mol Imaging 29(6):742-753. doi: 10.1007/s00259-002-0782-9
24. Maina T, Nock BA, Cordopatis P, Bernard BF, Breeman WAP, van Gameren A, van den Berg R, Reubi JC, Krenning EP, de Jong M (2006) Tc-99m Demotate 2 in the detection of sst(2)-positive tumours: a preclinical comparison with In-111 DOTA-tate. Eur J Nucl Med Mol Imaging 33(7):831-840. doi: 10.1007/s00259-006- 0068-8
25. Melacini G, Zhu Q, Goodman M (1997) Multiconformational NMR analysis of sandostatin (octreotide): equilibrium between beta-sheet and partially helical structures. Biochemistry 36(6):1233-1241. doi: 10.1021/bi962497o
26. Mitra S, Banerjee TS, Hota SK, Bhattacharya D, Das S, Chattopadhyay P (2011) Synthesis and biological evaluation of dibenz [b,f] [1,5] oxazocine derivatives for agonist activity at kappa-opioid receptor. Eur J Med Chem 46(5):1713-1720. doi: 10.1016/j.ejmech.2011.02.024
27. Nikolopoulou A, Nock BA, Maina T (2006) Tc-99m targeting of Sst(2)-expressing tumors by tetraamine-octreotide: first results in CA20948 cells and rat models. Anticancer Res 26(1A):363-366
28. Reubi JC, Waser B, Schaer JC, Laissue JA (2001) Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 28(7):836-846. doi: 10.1007/s002590100541
29. Rodziewicz-Motowidio S, Brzozowski K, Legowska A, Liwo A, Silbering J, Smoluch M, Rolka K (2002) Conformational solution studies of neuropeptide gamma using CD and NMR spectroscopy. J Pept Sci 8(5):211-226. doi: 10.1002/psc.384
30. Storch D, Behe M, Walter MA, Chen JH, Powell P, Mikolajczak R, Macke HR (2005) Evaluation of Tc-99m/EDDA/HYNIC0 octreotide derivatives compared with In-111-DOTA(0), Tyr(3), Thr(8) octreotide and In-111-DTPA(0) octreotide: does tumor or pancreas uptake correlate with the rate of internalization? J Nucl Med 46(9):1561-1569
31. Thakur ML, Kolan H, Li J, Wiaderkiewicz R, Pallela VR, Duggaraju R, Schally AV (1997) Radiolabeled somatostatin analogs in prostate cancer. Nucl Med Biol 24(1):105-113. doi: 10.1016/s0969-8051(96)00180-1
32. Vaidyanathan G, Friedman HS, Affleck DJ, Schottelius M, Wester HJ, Zalutsky MR (2003) Specific and high-level targeting of radiolabeled octreotide analogues to human medulloblastoma xenografts. Clin Cancer Res 9(5):1868-1876
33. von Guggenberg E, Penz B, Kemmler G, Virgolini I, Decristoforo C (2006) Comparison of different methods for radiochemical purity testing of [Te-99m-EDDA-HYNIC-D-Phe(1), Tyr(3)]-octreotide. Appl Radiat Isot 64(2):194-200. doi: 10.1016/j.apradiso.2005.07.019
34. Weiner RE, Thakur ML (2002) Radiolabeled peptides in the diagnosis and therapy of oncological diseases. Appl Radiat Isot 57(5):749-763. doi: 10.1016/s0969-8043(02)00192-6
35. Wild D, Schmitt JS, Ginj M, Macke HR, Bernard BF, Krenning E, de Jong M, Wenger S, Reubi JC (2003) DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 30(10):1338-1347. doi: 10.1007/s00259-003-1255-5